Clin2
NCT06753890Possibly a fitNot yet recruiting

Changkang granules for diarrhea-predominant irritable bowel syndrome

Diarrhea-predominant Irritable Boewl Syndrome

Part of Digestive system clinical trials.

This trial tests a Chinese herbal medicine called Changkang granules to see if it can reduce belly pain and diarrhea in people with irritable bowel syndrome (IBS) where diarrhea is the main symptom. It may help if your IBS is linked to stress or emotions, which is called 'liver qi affecting the spleen' in traditional Chinese medicine.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
520 people
Ages
18 years to 65 years
Study type
Interventional

Who can take part

  • You are between 18 and 65 years old.
  • You have been diagnosed with IBS with diarrhea (using the Rome IV criteria) and have had belly pain and loose stools for a while.
  • You have had a colonoscopy in the past year that showed no serious problems (or only minor issues like small polyps or hemorrhoids).
  • You are not taking certain medicines for IBS, depression, or anxiety, and you have not taken them in the last 4 weeks.
  • You do not have other digestive diseases (like Crohn's disease, ulcers, or celiac disease) or other health conditions like diabetes or thyroid problems.
  • You are not pregnant or breastfeeding, and you agree to use birth control if needed.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07610434Not yet recruiting· Phase 3
Chinese herbal capsules for diarrhea-type irritable bowel syndrome

This study tests a traditional Chinese medicine capsule called Changji'an to see if it safely reduces diarrhea, pain, and bloating in people with diarrhea-type irritable bowel syndrome. These symptoms are thought to be caused by 'liver Qi invading the spleen.'

Beijing, Dongcheng District
NCT07061184Not yet recruiting· Phase 4
Herbal medicine for diarrhea-predominant irritable bowel syndrome

This trial tests a Chinese herbal medicine called Fengliao Changweikang to see if it helps people with diarrhea-predominant irritable bowel syndrome (IBS-D). Each person tries the treatment and compares it to a placebo to find out if it works for them personally.

Beijing, Beijing Municipality
NCT07721012Not yet recruiting· Phase 2
Traditional Chinese medicine pill for diarrhea-type irritable bowel syndrome

This study tests a traditional Chinese medicine pill called Huanghou Zhixie Diwan for people with irritable bowel syndrome with diarrhea (IBS-D). It aims to reduce belly pain and improve stool consistency, and may offer a new option for those who haven't found relief with standard treatments.

Beijing
NCT07715760Not yet recruiting
Herbal formula for overlapping stomach and bowel symptoms

This trial tests a Chinese herbal formula called Hewei Anchang for people who have both functional dyspepsia (stomach pain or discomfort) and diarrhea-predominant irritable bowel syndrome (IBS-D). The goal is to see if the formula improves symptoms and understand how it works.

Beijing, Beijing Municipality
NCT06737666Recruiting· Phase 1
Tong-Xie-Yao-Fang for Diarrhea-Predominant IBS

This trial tests an herbal formula called Tong-Xie-Yao-Fang for people with diarrhea-predominant irritable bowel syndrome (IBS-D). It aims to see if the treatment helps symptoms and how it works. Healthy volunteers are also needed for comparison.

Beijing, Beijing Municipality
NCT06696261Recruiting· Phase 3
Lianxiaxiaopi granules for post-meal fullness

This study tests a Chinese herbal granule (Lianxiaxiaopi) for people with postprandial distress syndrome, a condition where you feel full too soon or uncomfortably full after eating. The goal is to see if it helps reduce these symptoms.

Beijing, Beijing Municipality

Hear when a new Diarrhea-predominant Irritable Boewl Syndrome trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.